- Home
- NOG vs CRSP Comparison
NOG vs CRSP Comparison
Compare NOG & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOG
- CRSP
- Stock Information
- Founded
- NOG N/A
- CRSP 2013
- Country
- NOG United States
- CRSP Switzerland
- Employees
- NOG N/A
- CRSP N/A
- Industry
- NOG Oil & Gas Production
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOG Energy
- CRSP Health Care
- Exchange
- NOG Nasdaq
- CRSP Nasdaq
- Market Cap
- NOG 3.6B
- CRSP 3.4B
- IPO Year
- NOG N/A
- CRSP 2016
- Fundamental
- Price
- NOG $42.04
- CRSP $40.53
- Analyst Decision
- NOG Strong Buy
- CRSP Buy
- Analyst Count
- NOG 11
- CRSP 19
- Target Price
- NOG $47.09
- CRSP $77.13
- AVG Volume (30 Days)
- NOG 1.5M
- CRSP 1.8M
- Earning Date
- NOG 02-20-2025
- CRSP 02-19-2025
- Dividend Yield
- NOG 3.90%
- CRSP N/A
- EPS Growth
- NOG 8.03
- CRSP N/A
- EPS
- NOG 8.29
- CRSP N/A
- Revenue
- NOG $2,000,332,000.00
- CRSP $202,829,000.00
- Revenue This Year
- NOG $30.40
- CRSP N/A
- Revenue Next Year
- NOG $5.79
- CRSP $724.16
- P/E Ratio
- NOG $5.07
- CRSP N/A
- Revenue Growth
- NOG 20.88
- CRSP 19.31
- 52 Week Low
- NOG $31.13
- CRSP $36.52
- 52 Week High
- NOG $44.31
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- NOG 69.40
- CRSP 44.09
- Support Level
- NOG $35.59
- CRSP $36.52
- Resistance Level
- NOG $42.35
- CRSP $40.99
- Average True Range (ATR)
- NOG 0.85
- CRSP 1.78
- MACD
- NOG 0.60
- CRSP 0.23
- Stochastic Oscillator
- NOG 95.41
- CRSP 51.68
About NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. Company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), and the Appalachian Basin (Pennsylvania and Ohio).
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.